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Does Normalizing Gut Microbiota Decrease Exacerbation In IBD
Franchesca Cook, RN, BSN, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract
Inflammatory bowel disease (IBD) including Crohn’s Disease (CD) and
Ulcerative Colitis (UC) has become a more common diagnosis. The
number of screenings for IBD has increased, drawing more attention to
finding the cause. Researchers are finding that a change in diet, increased
stress levels, and overuse of antibiotics may contribute to IBD by changing
the gut microbiota (Skrautvol et al., 2011; Bernstein, 2010). Prebiotics and
probiotics, an individualized anti-inflammatory diet, and lifestyle
modification to decrease stress are all currently undergoing evaluation to
discover a possible role in the reversal of IBD insult to the normal flora of
the gut. This literature review examined IBD studies within the past eight
years, including children and adults age 10-76, male and female who suffer
from IBD and address gut microbiota. Articles were reviewed from EBSCO
and PubMed. Cammorata et al. (2015) conducted research on fecal samples
from patients with IBD (n=330) and healthy control (n=165) using a
Dysbiosis Index (DI). Dysbiosis was associated with a score of >2. All
healthy controls were <2 and IBD patients >2. This was confirmed with an
Illumina MiSeq test with P=<0.001. Kabeerdoss, J. et al. (2013) researched
biopsies from colonic mucosa of patients with IBD (n=60) compared with
controls (n=30) undergoing screenings. A decreased ratio of Firmicutes to
Bacteroidetes was identified in IBD patients with significance of P=0.0014
proving an altered gut flora in IBD patients. The population of patients
examined with IBD who are able to restore their gut microbiota will likely
decrease symptoms and decrease the need for long-term treatment with antiinflammatory medications. Further research is needed to identify specific
imbalances in microbiota with the application of results to create an
individualized plan to restore gut flora as a key treatment to achieve and
maintain remission in IBD patients.

Introduction
•Inflammatory Bowel Disease (IBD) has been increasing in incidence over the
past decade. The effects of the disease on an individual and the potential lifelong cost of medical treatment are rationales to find and treat the cause of IBD.
Researchers are evaluating altered gut flora as a cause of IBD. Dysbiosis was
identified as a feature of IBD and interventions directed at themicrobiome may
be indicated in thetherapy of IBD (Kabeerdoss et al., 201).

Statement of the Problem
•Patients diagnosed with ID are faced with the potential of life-long antiinflammatory drugs, steroiBds, biological drugs, and even surgery to decrease
or control symptoms. Documented side effects of these treatments are
decreased immunity, renal failure, hepatotoxicity, exacerbations of the disease,
myocarditis, blood dyscrasias, and anemia. The cost of the medication, side
effects, hospitalizations and absenteeism from work add to the burden of
patients with IBD.

Research Question
In patients with IBD will restoring gut microbiota
eliminate or decrease the need for long-term
treatment with medications?

Literature Review

Discussion

Applicability to Clinical Practice

• Patients with IBD are in a state of gut dysbiosis (Ballal, Gallini, Segata,
Huttenhower, & Garrett, 2011). Evidence supports the theory that
microbiota is altered in IBD patients (Kabeerdoss, Jayakanthan,
Pugazhendhi, & Ramakrishna, 2015). See Figure 1. Eventually, due to
disruption of homeostasis in the gut flora, an inflammatory response occurs
resulting in erosion of the mucosa of the gastrointestinal tract.
Malabsorption of essential vitamins, minerals and nutrients is the result,
leaving the body in a suboptimal state.

Identifying patients at risk for development and exacerbation of IBD is an
important role for primary care providers. As genetic testing, fecal testing and
microbiota testing becomes more widely used IBD could be prevented in the
future. Research has correlated nutrition’s impact on the gut microbiota but
larger studies are needed. Patients with IBD have an imbalance in their gut
organisms that when balanced could create a state of normobiosis. IBD-AID
as a nutritional guide is an optimal approach to healing and reestablishig
homeostasis of the gut microbiota (Olendzki, Silverstein, Cave, & Baldwin,
2014). The success of the IBD-AID trial warrants a larger study group
utilizing the IBD-AID diet vs the currently used anti-inflammatory drugs,
steroids, biological drugs, and surgery. Similar results would support the
benefit and the promote the use of the IBD-AID diet as a standard of care.
Primary care providers and nutritionists can assist IBD patients, or those at
risk of developing IBD due to genetic indicators, in staying adherent to an
individualized nutrition plan that could decrease the need for the mainstay
medications currently used to treat IBD. Encouraging patient compliance and
accountability for health is ongoing and imperative for success in the treatment
of IBD. Nutrition in the form of an anti-inflammatory diet has the potential to
decrease the need for costly anti-inflammatory drugs, steroids, biological
drugs and decrease their dangerous side effects but more research is needed to
prove this.

•Casen et al. (2015) termed the microbiota in a healthy patient “normobiosis”. The purpose of
this study was to obtain fecal samples and examine the relationship between dysbiosis and
patients with IBD. Adult male and female patients ages 17-76 (n=330) were selected both with
IBD and a control group of healthy individuals (n=165). The fecal samples were probed
targeting approximately 300 bacteria to identify dysbiosisusing the GA-map Dysbiosis Test
(GA-test) to determine a Dysbiosis Index (DI). In this sample, a DI of >2 was associated with
dysbiosis. In all samples collected from healthy individuals results were <2 with a mean of 1.72
and in IBD both treatment naïve and in remission were >2 with a mean from 3.15-3.3. Results
confirmed dysbiosis in 70-80% of IBS patients, IBD patients untreated, and IBD in remission
vs 16% in healthy controls (Casen, et al., 2015). Firmicutes, Proteobacteria, Actinobacteria
and Ruminociccus gnavus were predominant bacteria found associated with IBD.
Figure 1. Ratio of Firmicutes (C. coccoides plus C. leptum) to Bacteroidetes in the mucosal
microbiota. The Figure shows the ratio in patients with CD and UC. CD-N and CD-Ab refer to
Crohn’s disease normal and abnormal mucosa. UC-N and UC-Ab refer to ulcerative colitis normal
and abnormal mucosa. Significant P values are shown above the bars in the Figure. None of the
other differences was significant. IBD biopsies showed a significantly lower ratio compared with
controls. (Kabeerdoss, Jayakanthan, Pugazhendhi, & Ramakrishna, 2015)

•Kaberdoss et al. (2013) studied the colonic mucosa of patients with IBD and healthy
controls to determine alteration in microbial communities Biopsies of colonic mucosa was
• Research has found genetic alterations of genes such as the NOD2 risking
obtained in 32 patients with UC, 28 with CD, and 30 healthy controls during colonoscopy.
the development of IBD (Leone, Chang, & Devkota, 2013). Atg16L1,
Results produced a ratio of Firmicutes to Bacteroidetes was significantly decreased in patients
IRGM, and IL-23R were other altered genes associated with patients with
with CD and UC compared to healthy controls indicating dysbiosis in IBD patients with
IBD (Ballal, Gallini, Segata, Huttenhower, & Garrett, 2011). Testing for
P=0.0014 (Kabeerdoss, Jayakanthan, Pugazhendhi, & Ramakrishna, 2015). Dysbiosis was
genetic components is not routinely performed in IBD but may have
identified as a feature of IBD and interventions directed at the microbiome may be indicated
potential to prevent onset. A study of using this testing as a predictor may
be useful.
in the therapy of IBD (Kabeerdoss, Jayakanthan, Pugazhendhi, & Ramakrishna, 2015).
• Study of fecal samples are proving helpful in identifying specific bacteria
involvement and dysbiosis in IBD (Casen, et al., 2015). Fecal and mucosal
•Olendski, B. et al. (2014) utilized an Anti-Inflammatory Diet (IBD-AID) to help treat
sampling to identify dysbiosis would prove beneficial and establish a
symptoms of IBD. Dysbiosis is the theory behind this diet theorizing certain carbohydrates
foundation from which to treat the patient as an individual. The causative
contribute to the proliferation of pathogenic bacteria (Olendzki, Silverstein, Cave, &
imbalance of microbiota could potentially be replaced if properly
Baldwin,2014). Eleven of 40 patients chose to remain on the diet and were reviewed by
identified.
the Harvey Bradshaw Index (HBI) or the Modified Truelove and Witts Severity Index
• The theory that if diet is a causative component of IBD then diet should be
a therapeutic treatment in IBD is of growing interest. Restoring the gut
(MTLWSI) before and after the diet (Olendzki, Silverstein, Cave, & Baldwin, 2014).
microflora through proper nutrition may be a key component in the
The MTLWSI mean was 7 (range 6-8) and the follow-up mean was 0. The average decrease
treatment and prevention of IBD (Olendzki, Silverstein, Cave, & Baldwin,
in the HBI was 9.5 and MTLWSI 7. The sample group was fairly small and only
2014). Nutrition could be a successful adjunct in the treatment of IBD,
approximately 25% were compliant for four weeks (Olendzki, Silverstein, Cave, & Baldwin,
decreasing the need for medication and preventing the need for surgical
2014).
intervention in these patientsThe IBD-AID diet was 100% successful in
decreasing the symptoms and dosage of medication of the IBD patients
who complied with the diet but the study was small. The need for a larger
cohort study focusing on an individualized patient nutritional plan is
needed as a result (Olendzki, Silverstein, Cave, & Baldwin, 2014).
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